ReviewVirologica Sinica2026
The role of T cells in influenza infection and vaccination.
Review in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- mRNA-1010 and the Future of Seasonal Influenza Prevention: Towards Next-Generation Respiratory Vaccination.Vaccines · 2026Article
- Conserved Influenza Epitopes Delivered via MHC-I-Functionalized Nanocarriers Induce Influenza-Specific CTL Responses.Immune network · 2026Article
- AI-Driven Approaches for the Detection, Classification, and Surveillance of Viral Pathogens: Current Advances, Challenges, and Future Directions.Pathogens (Basel, Switzerland) · 2026Review
- Algorithm-Optimized H5 Influenza mRNA Vaccine Induces Broad Immune Responses.International journal of molecular sciences · 2026Article
- A semi-replicating VSV (srVSV)-based platform for developing broad-spectrum mucosal vaccines against influenza A viruses.Virologica Sinica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza virus infections cause significant illness or death every year, becoming a serious health risk. Currently, influenza vaccines mainly induce responses to antibodies against specific strains, but they do not effectively induce effective T cell-mediated immunity. Humoral immunity relies on the production of antibodies that bind to surface proteins (such as hemagglutinin and neuraminidase) to combat the virus. These antibodies envelope the virus to prevent it from invading cells and also label the virus for phagocytic cells to clear. T cell-mediated immunity relies on cytotoxic cells to kill infected cells to combat the virus. Cytotoxic T cells rely on viral proteins on the surface of infected cell to recognize them. This enables the detection of more viral proteins, such as internal proteins like nucleoproteins. A better understanding of the mechanism by which T cells combat influenza is helpful for vaccine development. In this review, we elaborate on the role of T cells in enhancing anti-influenza immune defense. In addition, we explore the possibility that new influenza vaccines can induce such T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.